Vapogenix is a clinical-stage company developing a new class of non-narcotic analgesics for localized pain. Its products are formulated volatile anesthetics (VAs); currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. The company's core products focus on treating wound pain, localized inflammatory pain and pain associated with venipuncture, venous cannulation and minor dermatological procedures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/09/16 | $8,200,000 | Series C |
Pamoja Capital | undisclosed |
